Let's take a look at what's happening in the world of pharmacy and healthcare.
SoftWriters and SDS Rx Partner to Revolutionize LTC Pharmacy Delivery
SoftWriters, a leader in long-term care (LTC) pharmacy technology, and SDS Rx, a last-mile delivery provider, have announced a new partnership to streamline the delivery process for LTC pharmacies.
This collaboration integrates SoftWriters' FrameworkLTC software with SDS Rx's delivery technology and courier services. Key benefits for pharmacies include:
Improved oversight by tracking delivery schedules, packing slip exchanges, and real-time status updates.
Enhanced compliance from improved packing slip data and prescription-level proof of delivery.
Streamlined support that resolves issues faster with direct access to delivery data.
And deeper insights through detailed delivery milestone metrics for better workflow management.
"By leveraging our collective strengths, we can offer a comprehensive solution tailored to the unique needs of LTC pharmacies," said Scott Beatty, President of SoftWriters.
This partnership marks a significant step forward in LTC pharmacy delivery, offering pharmacies improved efficiency, compliance, and peace of mind.
Primary Care Gets Cost-Conscious as Elation and Surescripts Team Up
Elation and Surescripts have joined forces to bring real-time prescription cost data right into the doctor's office. This arms clinicians with critical financial information during consultations, paving the way for:
Transparent medication discussions in which patients get clear cost insights upfront, enabling collaborative treatment decisions.
Improved medication adherence with affordable options that lead to better compliance and clinical outcomes.
Healthcare cost reduction from ensuring that patients receive and stick to cost-effective medications and avoiding potential downstream costs tied to non-adherence.
Better Therapeutics Publishes Report Demonstrating Effectiveness of AspyreRx Digital Treatment
Better Therapeutics, a company developing digital treatments for heart and metabolic diseases, announced today that their prescription-only digital behavioral treatment for type 2 diabetes, AspyreRx, has been shown to be both more effective and less expensive than standard care alone.
The study, titled "Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes'' has been published in Advances in Therapy. The results show that AspyreRx, when combined with standard care, led to more life years gained and improved quality of life for patients with type 2 diabetes, at a lower cost than standard care alone. The study also found that AspyreRx was cost-effective at a willingness-to-pay of $100,000 per quality-adjusted life year, with an incremental net monetary benefit of $17,443.
This means that for every dollar spent on AspyreRx, the healthcare system saves $17.43. Savings were primarily driven by a reduction in drug costs, followed by reductions in adverse event costs. This study adds to the growing body of evidence supporting the potential of digital therapeutics to improve patient outcomes and reduce healthcare costs.
SoftWriters and SDS Rx Partner on LTC Delivery; Elation and Surescripts Team Up; And Better Therapeutics Publishes Report on AspyreRx Digital Treatment